Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
Amgen sheds around 40 staffers amid continuing struggles
(2d)
Study of Yescarta patients reveals genetic red flags for CAR-T therapy side effects
(2d)
Merck stages expanded access to monthly HIV PrEP pill ahead of approval
(2d)
Sanofi abandons plan to seek approval for eczema drug from $1.1B Kymab buyout
(2d)
Scribe records upsized $129M IPO to bankroll lipid-lowering genetic meds
(2d)
Chutes & Ladders—Biogen R&D vet gets in Formation
(3d)
Scancell to go public after winning reverse merger bid for troubled Neuphoria
(3d)
Lilly’s triple-G drug hits 22.6% weight loss, but impact on reducing cardio risk is less clear
(3d)
Roche Diagnostics growth remains muted amid China headwinds
(3d)
Australian biopharma Clinuvel to shed up to 20% of workforce in move to US
(3d)
Roche drops TCE for lupus, but hasn’t given up on autoimmune cell therapies
(3d)
FDA clears Johnson & Johnson’s surgical robot for ‘the next era in surgery’
(3d)
NIH joins Trump’s $5B AI mission with biomedical research push
(4d)
House passes bill directing FDA to update animal testing rules
(4d)
Royalty Pharma pens $425M deal for slice of sales on AstraZeneca’s ATTR drug
(4d)
Celldex ends skin disease program after failing phase 2 test
(4d)
‘We’re moving quickly’: Startup bags rare disease drug as Thiel-backed CEO eyes $50M fundraise
(5d)
Biotech industry leaders file brief backing FDA against ‘malicious’ mifepristone challenge
(5d)
Crystalys mines $130M series B to push gout drug through phase 3
(5d)
Why Novartis CEO ended his ADC holdout for $1.5B Myricx deal
(5d)
BioPharma Dive
Sanofi halts development of troubled immune drug in eczema
(2d)
Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myeloma
(2d)
Scribe secures $129M in a rare gene editing IPO
(3d)
FDA panel endorses broader use of certain peptides
(3d)
Lilly, with new data, to seek FDA approval of obesity drug retatrutide
(3d)
Vertex was sole bidder in high-premium Crinetics acquisition
(4d)
GSK lung cancer drug gets speedy approval following $10.6B deal
(4d)
Arrowhead hits ‘best-case scenario’ with latest results for fat-lowering drug
(4d)
Trump threatens tariffs on imported generic drugs
(4d)
Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease study
(4d)
Crystalys nets $130M more to push gout drug through late-stage tests
(4d)
Agios scraps sickle cell drug
(5d)
Novo sues Lilly, alleging ‘misleading’ advertising of obesity drugs
(5d)
Dimension restocks with $800M to capitalize on AI’s ‘rapid ascent’
(5d)
Novartis climbs on upbeat drug sales as key readouts loom
(5d)
Tempus to buy cancer test-maker Personalis for $1.5B
(6d)
Tempus to acquire cancer test maker Personalis for $1.5B
(6d)
Pain drugmaker Latigo outlines plans to go public
(6d)
Bristol Myers to build ‘powerful’ AI factory; Samsung Biologics bids for peptide maker
(6d)
Jasper gets a lifeline in merger with immune drugmaker Kira
(1w)
Endpoints News
Anthropic’s life science plans; Novartis CEO on China deals; and more
(1d)
Amgen shares new Tavneos analysis in effort to resolve FDA dispute
(2d)
Ipsen’s Bylvay fails key trial in children with rare liver disease
(2d)
Biogen’s Alzheimer’s data spur excitement, confusion about tau-targeting drugs
(2d)
Novo asks court to block Lilly ads; Merck strikes HIV PrEP deal
(2d)
CHMP recommends Minoryx’s ALD drug, rejects Zevra’s Meplyffa
(2d)
Michael Ehlers joins Formation Bio to lead R&D Black Diamond co-founder dies at 67
(2d)
Sanofi nixes Kymab-originated OX40L antibody in atopic dermatitis
(2d)
Gene editor Scribe starts second-half IPO spree with $129M listing
(2d)
FDA adcomm votes in favor of lifting restrictions on popular wellness peptide BPC-157
(3d)
FDA to end pilot aimed at preventing production issues
(3d)
Sartorius reduces revenue by €26M to refund Trump tariffs to customers
(3d)
Merck CEO cautions Congress on imposing limits on Chinese dealmaking
(3d)
Scancell plans Neuphoria merger; AstraZeneca wins EU nod for cancer drug
(3d)
Biogen counts on drugs from Apellis deal to patch Leqembi's slow sales
(3d)
What’s behind the proposed pullback on remote patient monitoring
(3d)
Repligen’s $1.5B buy for BioLife; BeOne’s $300M US expansion
(3d)
Lilly's triple agonist heads to regulators after two more Phase 3 obesity wins
(3d)
Roche says it is thoughtful on token use for AI, shelves a drug from Carmot buy
(3d)
Exclusive: Obesity biotech Verdiva hires ex-Metsera CMO as crucial readouts near
(3d)
BioSpace
Sanofi’s $1.4B Kymab bet falters again as atopic dermatitis trials scrapped
(2d)
Amgen deploys patients to defend troubled Tavneos in FDA hearing request
(2d)
Lilly’s $3.8B psychedelics bet won’t open the M&A floodgates
(2d)
Summit has less than a year of cash runway left as PD-1/VEGF verdict nears
(2d)
Roche cans one Carmot obesity asset as another shows best-in-class potential
(2d)
BeOne commits $300M to US manufacturing expansion, creating 120 new jobs
(3d)
Lilly preps FDA run for ‘triple-G’ weight loss drug with Phase 3 data
(3d)
Roche's late stage pipeline "so full" CEO Schinecker not feeling pressure to add on
(3d)
GSK’s $10.6B Nuvalent bet pays off early as FDA approves lung cancer drug
(3d)
Nordic biotech’s next act: From fragmentation to global force
(3d)
Biopharma layoffs must double in H2 for 2026 to match 2025 cuts
(3d)
Make or break: commercial hires critical for success
(3d)
Webinar: From Clinical to Commercial: Talent Strategies for Biopharma Growth
(4d)
Summit and Akeso sharpen case for ivonescimab with new Western data
(4d)
Arrowhead puts pressure on Ionis with positive data for triglyceride lowering drug
(4d)
Repligen strikes $1.5B BioLife buyout to bag cell therapy product pharmas rely on
(4d)
6 companies hiring in Cambridge now
(4d)
US ‘eroding’ lead in rare diseases a matter of national security: Report
(4d)
Novartis scraps mid-stage radiopharma asset as Pluvicto soars
(4d)
Q2 earnings underway, FDA’s CRL kerfuffle, IPOs full speed ahead in H2
(4d)
STAT News
I led the FDA’s food safety and nutrition center. Here’s what people are missing about the cyclospora outbreak
(2d)
FDA advisory panel narrowly rejects compounding of one peptide, back another
(2d)
There are already more U.S. measles cases this year than in all of 2025
(2d)
Up and down the ladder: The latest comings and goings
(2d)
Fatal gene-editing trial in China raises ethics and oversight questions
(2d)
We’re reading about an FDA panel and peptides, a Merck license for an HIV pill, and more
(2d)
A new, separate outbreak of the diarrhea-causing parasite
(2d)
Merck strikes voluntary licensing deals in poor countries for an experimental HIV prevention pill
(2d)
White House offers its science blueprint: More AI, less life sciences
(2d)
Senate advances MAHA-friendly bill for food warning labels and junk food ad bans
(2d)
The U.S. pharmaceutical supply chain problem is not about China
(2d)
I may be one of the last middle-class medical students who could afford to become a doctor
(2d)
In win for RFK Jr., FDA advisory panel narrowly votes to allow compounding of unapproved peptides
(3d)
U.S. health officials are investigating a new outbreak of a diarrhea-causing parasite
(3d)
European regulators take steps to bolster clinical trial transparency
(3d)
Popular insulin product enters shortage as other pens leave market
(3d)
Senate health panel delays vote on CDC nominee
(3d)
What’s in the last-minute flurry of health care bills?
(3d)
FDA panel confronting peptide controversy
(3d)
A father’s mission to save his daughter, and allegations on telehealth GLP-1 prescribing
(3d)
BioPharma Trend
Seven HealthTech Trends In Europe To Watch
(1mo)
Self-Care Is Not a Product, It’s Critical Infrastructure: Why We Must Work Together to Make Health Systems Resilient.
(1mo)
Ginkgo Datapoints, Tangible Scientific, and Inductive Bio launch ADME-One, a packaged ADME service for hit identification
(2mo)
AI Won't Replace Clinical Programmers. It Will Split Them Into Two Groups.
(2mo)
Novo Nordisk and OpenAI Team Up to Integrate AI from Discovery to Supply Chain
(3mo)
Life Biosciences Gets $80M as Cellular Rejuvenation Enters the Clinic
(3mo)
Jeito Closes €1B Fund, Europe's Largest Independent Biopharma Raise
(3mo)
Anthropic Pays $400M for an AI Biotech With Fewer Than Ten People
(3mo)
Epia Neuro Wants to Decode Brain's Movement Intentions After Stroke
(3mo)
Generare Raises €20M to Explore Uncharacterized Chemical Space from Microbial DNA
(3mo)
Enveda’s AI-Discovered Drug Shows Early Atopic Dermatitis Relief
(3mo)
Lilly Signs $2.75B AI Drug Discovery Deal With Insilico
(3mo)
Meta Open Sources Foundation Model That Predicts Brain Responses to Speech, Video, and Text
(4mo)
Two Ex-GSK AI Leads Go Stealth with a New Oncology Drug Discovery Startup
(4mo)
Tempus and Daiichi Sankyo Partner on AI-Guided Cancer Biomarker Discovery
(4mo)
Bioptimus Launches Multimodal Tissue Atlas Across Three Continents
(4mo)
Merck Signs $20M Deal With Quotient to Find IBD Targets Using Somatic Genomics
(4mo)
insitro and Bristol Myers Squibb Add New AI-Found Targets in ALS Research
(4mo)
Latent Labs Launches AI Agent for Antibody Design From a Single Text Prompt
(4mo)
Earendil Labs Gets $787M to Push AI-Designed Antibodies Toward the Clinic
(4mo)
Drug Channels
Direct-to-Patient: Transforming the Manufacturer Access Model
(2d)
2025 Gross-to-Net Realities at Eight Top Drugmakers: The Net Pricing Drug Channel Emerges
(5d)
2025 Gross-to-Net Realities at Eight Top Drugmakers: The Net Pricing Drug Channel Emerges
(5d)
Direct-to-Consumer Shouldn't Always Mean Direct-To-Mail-Order: Why Fulfillment Choice Matters
(1w)
Direct-to-Consumer Shouldn't Always Mean Direct-To-Mail-Order: Why Fulfillment Choice Matters
(1w)
The 340B Program Hit $100 Billion in 2025: Has It Become Too Big to Reform?
(2w)
The 340B Program Hit $100 Billion in 2025: Has It Become Too Big to Reform?
(2w)
Medicare Embraces Site-Neutral Payments. Why Haven't Employers?
(2w)
Medicare Embraces Site-Neutral Payments. Why Haven't Employers?
(2w)
Medicare Embraces Site-Neutral Payments. Why Haven't Employers?
(2w)
When Access Tightens, Prior Authorization Execution Becomes the Differentiator
(2w)
When Access Tightens, Prior Authorization Execution Becomes the Differentiator
(2w)
The Hidden Cost of 340B for Employers and Health Plans
(3w)
The Hidden Cost of 340B for Employers and Health Plans
(3w)
Drug Channels News Roundup, June 2026: PBM Shakeout Accelerates, 340B Enters a New Era, Rebate Questions Persist, Mark Cuban Wins Again, and Ge Bai’s HHS Nomination
(4w)
Drug Channels News Roundup, June 2026: PBM Shakeout Accelerates, 340B Enters a New Era, Rebate Questions Persist, Mark Cuban Wins Again, and Ge Bai’s HHS Nomination
(4w)
BlinkRx Insights: The Questions Manufacturers Wish They Had Asked Before Selecting a Patient Services Partner
(1mo)
BlinkRx Insights: The Questions Manufacturers Wish They Had Asked Before Selecting a Patient Services Partner
(1mo)
Pharmacist Salaries and Employment in 2025: Retail Declines, Hospital Gains
(1mo)
Pharmacist Salaries and Employment in 2025: Retail Declines, Hospital Gains
(1mo)
European Biotechnology Magazine
CHMP backs Minoryx’s rare disease drug two years after rejection
(2d)
Sanofi drops eczema drug from $1.1B Kymab deal
(2d)
Iceland-based Synaptiq launches with Nobias’ rare disease drug
(2d)
Fresenius launches €200M healthcare venture fund
(3d)
Neurimmune turns future royalties into $425m pipeline cash
(3d)
OMEICOS takes repurposed drug directly into Phase 3
(4d)
Novartis drops Phase 2 radioligand therapy
(4d)
Immitra Bio raises CHF 2.4M for in-vivo gene editing
(5d)
Phinomics Brings a New Layer of Cancer Biology from the U.S. to Berlin
(5d)
Samsung Targets Swiss CDMO PolyPeptide in $1.8 Billion Deal
(5d)
Brenus adds €11M to colorectal cancer vaccine development
(5d)
RNA medicine enters its second act
(6d)
Sightera raises €3M to advance AI-generated molecular glues
(6d)
GSK setback deepens P2X3 cough drug doubts
(6d)
Stepping up in Innsbruck
(6d)
Isomorphic megadeal lifts UK biotech funding to five-year high
(1w)
Orakl takes on four Sanofi cancer assets
(1w)
Mission Therapeutics refocuses on CNS and sells $292M kidney drug to Dimerix
(1w)
Lilly buys Europe-rooted AtaiBeckley for up to $3.8B
(1w)
Sanofi joins the mRNA vaccine patent wars
(1w)
Drug Hunter
zidebactam
(2d)
centanafadine
(3d)
thalidomide
(4d)
18F-florquinitau
(5d)
The NaV1.7 Disconnect: Pharmacologic Inhibition Does Not Recapitulate Genetic Loss
(6d)
Orum’s DACs Aim to Expand the Therapeutic Window of GSPT1 Degraders
(1w)
Emerging Strategies for GSPT1 Degradation
(1w)
nibrozetone
(2w)
zovegalisib (RLY-2608)
(2w)
Module 5, Section 3: Structure-Based Design
(2w)
How to “pHLIP” the Script on Drug Delivery
(2w)
ACT-1004-1239
(2w)
TERN-701
(3w)
Getting Large Molecules Into the Brain Through Transferrin Receptor-Mediated Delivery
(3w)
sparsentan
(3w)
avacopan
(3w)
islatravir
(4w)
May 2026 Patent Gazette
(4w)
Boron Neutron Capture Therapy: Precision Radiation With Targeted Delivery
(4w)
Module 5, Section 2: Ligand-Based Design
(4w)
Labiotech.EU
Munich’s biotech hub: Inside one of Europe’s leading life sciences ecosystems
(2d)
This nonprofit is building the ecosystem to cure epidermolysis bullosa
(2d)
Is an HIV cure possible? The future of HIV therapy
(4d)
Roche’s new gene sequencer on the market: where do current players stand?
(5d)
Inside one of Europe’s most advanced biotech innovation hubs
(5d)
Guinea worm: Why disease eradication is so rare
(6d)
How BIO-Europe is expanding beyond dealmaking in 2026
(1w)
Race for approval: biotechs accelerate bipolar disorder therapies
(2w)
Inside Takeda’s transformation: The pipeline strategy behind its next growth chapter
(2w)
End-to-end: Curia drives supply and scale for steroid and hormonal therapies
(2w)
Eight biotechnology companies leading the charge in Poland
(2w)
Top biotech deals in June 2026
(2w)
Turning cancer cell dependencies into targeted therapies
(2w)
11 biotech companies leading the way in Denmark
(3w)
The hidden innovation system behind drug repurposing
(3w)
Why Customer Experience Centers are becoming practical infrastructure for life sciences innovation in Europe
(3w)
The biggest biotech funding rounds in June 2026
(3w)
Novartis’ strategy in 2026: rebuilding the pipeline after Entresto
(3w)
The first PROTAC is here. What comes next in protein degradation?
(3w)
Prague: The up-and-coming biotech hub in Central Europe
(4w)
Bio IT World
The Most Expensive AI Mistake in Biotech Isn’t a Hallucination, It’s a Process Failure
(2d)
In Vivo CRISPR Therapy is One Step Closer to the Clinic
(3d)
Different Teams, Same Problem
(4d)
Winning Best of Show Again: A Reflection on MLADU, Research Data, and the Bio-IT World Community
(5d)
With AWS Help, UK Group Moves Toward Global AMR Intelligence Platform
(1w)
CFDE Promotes Collaboration to Build Creative and Practical Solutions to Data Challenges during the Bio-IT Hackathon
(2w)
How Sugar on Brain Cells May Be Driving Alzheimer’s and How a Common Joint Supplement May Be Making It Worse
(2w)
Signal Management Isn’t Broken; It Simply Belongs to a Previous Era
(2w)
Network Effects: John Quackenbush on How Networks Illuminate Biology Beyond Gene Expression
(2w)
Insilico Medicine Launches Phase III Trial for AI-Developed Drug
(3w)
Digital Brain Twin Tailor-Made for Autism Spectrum Disorder
(3w)
Follow the Money: Inflammatory Bowel Disease Oral Drug, Breast, Colorectal Cancer ADCs, Other Next-Gen, Novel Treatments
(4w)
Anthropic Launches Claude Science, Illumina's Spatial Insights Tool, Wellcome Sanger Institute, Google DeepMind AI Consortium
(4w)
SOPHiA GENETICS, Memorial Sloan Kettering Joint Venture, Illumina Launches Spatial Insights Tool, Wellcome Sanger Institute, Google DeepMind AI Consortium
(4w)
The Spatial Biology Bottleneck: Why AI Models Fail on Complex Tissue & What Actually Fixes It
(1mo)
Every Microbiome Tells a Changeable, Computable Story
(1mo)
Notes from the Trenches: A Computational Biologist’s View of Drug Discovery’s Digital Revolution
(1mo)
AI Readiness in Pharma – Getting the Foundation Right
(1mo)
AI Readiness in Pharma – Getting the Foundation Right
(1mo)
AI Readiness in Pharma – Getting the Foundation Right
(1mo)
GEN News
Colorectal Cancer Targeted with Mass-Produced iPSC-Derived Allogeneic T Cells
(2d)
Oral Antiviral Blocks Measles-Like Virus Transmission in Ferrets
(2d)
Single-Cell Atlas Simultaneously Maps 3D Genome Architecture and DNA Methylation
(2d)
Single-Cell Maps Reveal Genome Reorganization in Alzheimer’s Brain Cells
(3d)
Autism-Like Traits in Mice Improved After Single Rapamycin Dose
(3d)
Turning Solar Power Into Protein
(3d)
Midlife Brain Aging Linked to Immune Cell Remodeling, Blood-Brain Barrier Decline
(3d)
Samsung Proposes Offer to Acquire Swiss CDMO Specializing in Peptides
(3d)
Transmissible Cancer Discovered in Freshwater Fish
(4d)
Transcripta Bio Raises $24M for AI-Driven Neurological Disease Therapies
(4d)
AI Protein Engineering Model Designed for Biomanufacturing
(4d)
Cell-Therapy Manufacturers Get Creative on Checking Particulates
(4d)
Scaling Cell and Gene Therapy Manufacturing
(4d)
Hybrid Single-Use and Stainless-Steel Plants the Greener Option
(4d)
Engitix Licenses Lonza’s Technology to Advance ADC Therapies
(4d)
UCSD, IGI Partnership Expands CRISPR Innovation Across Health, Agriculture, and the Environment
(4d)
10x Clinical Expansion Advances with CLIA Lab Plans, Cleveland Clinic Partnership
(5d)
Blood Cancer Therapies Informed by Spatial Remodeling of Bone Marrow
(5d)
Revvity Creates Program to Equip Young Biotechs with Scalable Informatics Capabilities Sooner than Later
(5d)
Early Genomic Indicators of Praziquantel Resistance in Schistosoma mansoni
(6d)
Cure Today
Why I Chose a Treatment Break After Years of Living With Stage 4 Ovarian Cancer
(1d)
When the Scan Is Over but the Waiting Begins: Living With Lymphoma Scanxiety
(2d)
RASolute 302 and the Future of Pancreatic Cancer Treatment: Paul Oberstein, MD, on the KRAS Breakthrough
(2d)
Minimally Invasive Options in Rectal Cancer: TAMIS and Robotic Surgery
(3d)
Why I Don’t Want to Hear “You’ll Beat This” After a Metastatic Breast Cancer Diagnosis
(3d)
Diagnosed at 25 With Hodgkin's Lymphoma, She Says This Saved Her Life
(3d)
Cancer Care Leader Founds Program to Give Women Access to Cold Caps
(4d)
Choosing a Bra after a Mastectomy
(4d)
10 Things That Got Me Through Treatment ft. Edward Miskie
(5d)
The Healing Power of a Cancer Survivor Retreat During Scan Anxiety
(5d)
Biomarker Testing for Cancer: What Patients Should Know
(5d)
The Patient Voice: Asking Questions, Seeking Second Opinions in Lung Cancer Care
(5d)
Treatment Goals in Metastatic EGFR-Positive NSCLC, Advocacy Resources, and Closing Thoughts
(5d)
Family History of Cancer Fuels Oncology Nurse's Passion for Patient Care
(6d)
Clock Touches: An Advanced Balance Exercise for Patients with Cancer
(1w)
Wildfire Smoke and Cancer Risk: What Patients Should Know
(1w)
Balance Exercises for Patients With Cancer: How the Single-Leg Stand Builds Stability
(1w)
Supporting Community Health Workers as They Support Their Communities
(1w)
Why Faster Genomic Testing Could Change Cancer Care
(1w)
When the Caregiver Becomes the Patient
(1w)
Contract Pharma
Asymchem Carbapenem API Site in China Successfully Completes First FDA Inspection
(2d)
Federal Equipment Announces Turnkey Sale of Denison Pharmaceuticals Facility
(2d)
Neurocrine Biosciences Names New Senior Vice Presidents
(2d)
The Friday Brief for July 24, 2026: M&A Activity Heating Up
(2d)
Vir Biotechnology Appoints Brent Sabatini as Interim Principal Financial Officer
(2d)
FDA Approves NSCLC Treatment Acquired by GSK in Nuvalent Deal
(3d)
BeOne Medicines Plans $300M NJ Expansion, Bringing US Manufacturing Investment Over $1B
(3d)
Bora and Onconic Ink Manufacturing Pact for US Acid Blocker Tablet Clinical Development
(3d)
Famar Names New CEO
(3d)
Cold Chain Technologies Launches EcoFlex XS Reusable Shipper
(3d)
Thermo Fisher to Support ImmuPharma’s Kapiglucagon Program
(4d)
Schubert to Construct New Headquarters in Charlotte, North Carolina
(4d)
BostonGene, Kyoto University Announce Strategic Research Partnership
(4d)
Bayer, Kairos Pharma Collaborate to Boost Xofigo Effectiveness in Metastatic Prostate Cancer
(4d)
Formation Bio Appoints Michael Ehlers as Chief Scientific Officer & Head of RD
(4d)
Neurocrine Biosciences Appoints Samir Siddhanti as Chief Business Officer
(4d)
PolyPid, Azurity Pharmaceuticals Agree to Exclusive Commercial Partnership in US and Canada
(5d)
Wheeler Bio Welcomes Rajesh Beri as New Chief Development Officer
(5d)
From Potential to Practical at DIA 2026: Building Trust in AI at Scale
(5d)
Forge Biologics Launches AAV Development, cGMP Manufacturing Partnership with Restore Vision
(5d)
Pharma Times
GSK wins US approval for ROS1 lung cancer therapy
(3d)
Lundbeck secures FDA Fast Track for narcolepsy drug
(3d)
R1 Therapeutics begins global phase 2b trial of AP306 for hyperphosphatemia
(4d)
Mission Therapeutics divests MTX652 to Dimerix in deal worth up to $292 million
(4d)
Nouscom to present re‑treatment data in Lynch Syndrome at ESMO 2026
(5d)
ViiV Healthcare to unveil new HIV treatment data at AIDS 2026
(5d)
Jasper Therapeutics merges with Kira Pharmaceuticals
(6d)
EpilepsyGTx and ClearPoint Neuro join forces on targeted therapy
(1w)
NICE backs finerenone for heart failure
(2w)
EC approves Erbitux combination for first‑line treatment of BRAF V600E‑mutant mCRC
(2w)
FDA approves Leqembi Iqlik subcutaneous initiation dose for Alzheimer’s disease
(2w)
SMC recommends VEOZA for moderate to severe menopausal vasomotor symptoms
(2w)
SMC backs Columvi combination for second-line lymphoma treatment in Scotland
(2w)
Pluripotent stem cell trial for Huntington’s disease
(2w)
Jascayd gains UK licence for treatment of pulmonary fibrosis
(2w)
Grünenthal receives FDA designations for tegacorat in Duchenne muscular dystrophy
(3w)
Compass Pathways reports six‑month data confirming durable profile of COMP360
(3w)
Ferrer and Prilenia begin confirmatory study of pridopidine in Huntington’s disease
(3w)
Wegovy pill launches in UK as first daily oral GLP‑1 for weight management
(3w)
Sofinnova reports Myricx Bio to be acquired by Novartis
(3w)
Medcity News
Candid Health Snags $120M for AI RCM Platform
(9h)
Why Value-Based Care Only Works If You’ve Tamed Costs
(10h)
Medicine Understands Trauma’s Impact, But Rarely Asks About It
(10h)
A Prescription for Drug Costs: Inject Transparency and Improve Accessibility
(1d)
What Health Tech Investors Love in Founders — and What They Can’t Stand
(2d)
Priority Health Launches 2 Cancer Support Solutions with Color Health, Grail
(2d)
AI Will Reshape the Patient Experience
(2d)
Healthcare’s Next Source of Alpha Is Moving Upstream
(2d)
CRISPR Biotech Scribe Therapeutics Writes a New Chapter With $129M IPO
(2d)
Healthcare Investors Are Rewriting the ROI Playbook from Cost-Cutting to Cash Flow
(2d)
Who Broke the Healthcare System?
(3d)
Rethinking How Hospitals Measure Behavioral Health Success
(3d)
Four Ways Health Systems Should Plan for the Next Wave of Breakthrough Therapies
(3d)
Assured Health Secures $19M to Get Providers In-Network Faster with Agentic AI
(3d)
$10B M&A Deal Pays Off With GSK’s First Lung Cancer Drug Approval
(4d)
Headspace Teams Up with 4 Companies for Specialty Care
(4d)
Hidden in Plain Sight: The Cost Crisis in Women’s Healthcare
(4d)
What Healthcare Organizations Miss When It Comes to Reimbursement Accuracy
(4d)
Better Prescribing, Not Less Prescribing, Is What Behavioral Health Needs
(4d)
You Can Now Bet on Clinical Trials Like Playoff Games, But Health Execs Say It Crosses a Line
(5d)
Chemical & Engineering News
Rudy Marcus, developer of electron transfer theory, dies at 102
(2d)
ACS continues 150th celebration at EuChemS
(2d)
Policy Watch: DHS puts new limit on international student stays in the US
(2d)
C&EN weekly chemistry news quiz, July 24
(2d)
Ethylene capacity keeps shrinking in South Korea and Japan as Chinese competition mounts
(3d)
Dow sales and profits balloon as polymer prices jump
(3d)
Team USA brings home gold from 58th International Chemistry Olympiad
(3d)
Uncovered: Record-setting laser boosts cryo-electron microscopy
(3d)
Direct sugar chemistry streamlines C-aryl glycoside synthesis
(3d)
George Christou wins 2026 Herty Medal
(3d)
Fungi-based circuit boards could make industry greener
(3d)
Samsung makes a $1.8 billion bet on peptide production
(4d)
This breathalyzer can tell when you are burning fat
(4d)
Pharma learns to share as their AI demands more data
(4d)
Catalyxx plans biobased alcohol plant to improve European chemical security
(4d)
Business Watch: BASF warns about Iran War; Kira merges with struggling Jasper
(5d)
Recent EPA pesticide approvals spur further PFAS debate
(5d)
Ben Katz will ‘Mass Spec Everything’ to figure out what is in our food
(5d)
Enzyme engineers tackle protein damage from aging
(5d)
Trump dismantled Biden’s industrial policy for cleantech. Will the replacement succeed?
(6d)
The Pharma Letter
The week in pharma: action, reaction and insight – week to July 24, 2026
(13h)
Kaveri Therapeutics
(1d)
India’s pharma M&A market hits four-year high on blockbuster deals
(1d)
FDA approval for first-in-class in ADHD drug Simtriyo
(1d)
July 2026 EMA/CHMP medicines recommended for approval
(2d)
The next five years in bladder cancer: towards more predictive, personalized and less invasive care
(2d)
Merck & Co unveils early access strategy for once-monthly HIV prevention pill
(2d)
Lilly's retatrutide successful in two additional Phase III obesity trials
(2d)
Siegfried and Lonza lead four-way CDMO race in outsourced HPAPI
(2d)
Sanofi drops development of amlitelimab in atopic dermatitis
(2d)
J&J reports strong survival gains with Tecvayli-Talvey regimen in myeloma
(2d)
J&J reports strong survival gains with Tecvayli-Talvey regimen in myeloma
(2d)
BeOne Medicines adds $300M investment in US site
(2d)
FDA panel narrowly backs two peptides for compounding list
(2d)
Neurocrine bolsters senior ranks as it builds beyond Ingrezza
(2d)
TGA safety warnings on GLP-1 RAs and rare vision disorder drugs
(2d)
Verdiva Bio
(2d)
Abivax builds out commercial team as it readies obefazimod for US launch
(2d)
Almirall builds on biologics as first-half earnings climb
(2d)
Almirall builds on biologics as first-half earnings climb
(2d)
Targeted Oncology
MCED Testing: Preparing for the Next Era of Cancer Risk Assessment
(8h)
Biomarkers Beyond High TMB or MMR-D May Be Needed for ICIs in Sarcomas
(11h)
Community Clinical Trials and the Lung Cancer Pipeline
(13h)
From Genetic Testing to Personalized Cancer Prevention
(1d)
Ethical Challenges Behind Genome Sequencing and Precision Medicine
(1d)
How Inherited BRCA Mutations Shape Breast Cancer's Genomic Behavior and Point Toward a New Treatment Paradigm
(1d)
Navigating CAR T Decision-Making in R/R DLBCL
(2d)
On-Body Injectors Point to At-Home Care, but Hurdles Remain in US
(2d)
Scaling Genetic Counseling in Community Oncology
(2d)
Changing ADC Choices for HR+/HER2–Breast Cancer
(2d)
RASolute 302 and the Future of Pancreatic Cancer Treatment: Paul Oberstein, MD, on the KRAS Breakthrough
(2d)
First Patient Dosed in Trial of HLX-4310 for Relapsed/Refractory Osteosarcoma
(2d)
Why Awareness of Alcohol's Breast Cancer Risk Still Lags Decades Behind Tobacco
(2d)
Considering the Applications of On-Body Injector for Myeloma in Community Practice
(3d)
Teclistamab/Talquetamab Reduces Risk of Progression by 89% in R/R Multiple Myeloma
(3d)
Phase 1 Findings Support PSMA-PET–Guided Patient Selection for Radio-ADC in mCRPC
(3d)
Broadening Access to Genetic Testing in Community Practice
(3d)
FDA Grants Priority Review to Talazoparib Plus Enzalutamide for HRR-Altered mCSPC
(3d)
How Genome Sequencing Enables Precision Cell and Gene Therapies
(3d)
IMNN-001 Plus Chemo Cuts MRD Rate in Frontline Ovarian Cancer
(3d)
MedWatch
Novo Nordisk's tablet sales continue to rise following a new subsidy scheme in the US
(2d)
Sanofi discontinues eczema treatment following strategic review
(2d)
Demant grew market share among US veterans in June
(2d)
The legal battle continues – Novo now seeks a temporary ban on Eli Lilly's advertisements
(2d)
Genmab fails to meet goals in Phase 3 cancer trial
(2d)
Novo Investors: Lawsuit against Eli Lilly is apt
(2d)
US lawyer on the Novo lawsuit: It's about changing public perception
(2d)
Leo Pharma to significantly scale back its Russian operations by 2027
(2d)
Johnson & Johnson reports positive data from clinical trial of bone marrow cancer treatment
(2d)
Analyst on Leo Pharma's operations in Russia: Bad for reputation
(3d)
Eli Lilly presents positive safety data but postpones weight-loss candidate application
(3d)
US hearing aid company Eargo closes
(3d)
GN Hearing's Italian buyer elated after upgraded recommendation
(3d)
Researchers detect slight correlation between hair loss and slimming drugs
(3d)
Lundbeck receives FDA advantage for new sleep drug candidate
(3d)
IO Biotech founder brings key lessons to new top job: “I can get through a crisis”
(3d)
Summer series: Ophthalmologist's mission in Ghana is the highlight of the year for Norlase's CEO
(3d)
Leo Pharma's Russian operations could pose a challenge to its IPO plans
(3d)
Roche outperforms growth target in year's first half
(3d)
Compounders hold onto one-fifth of the US weight-loss market
(4d)
In The Pipeline
Clinical Failure Rates Over the Decades: Yikes
(2d)
The Assault On Science Funding Continues
(3d)
Thoughts on the "Netflix Analogy"
(4d)
Benchmarking the Benchmarks
(5d)
More Pancreatic Cancer Vaccine Progress - Treatment and Preventative
(6d)
More Condensate Secrets Revealed
(1w)
The Battle For Sickle Cell
(2w)
Tau In the Clinic, Again
(2w)
Amyloidosis Continues to Fight Back
(2w)
Chemical Onshoring of All Kinds
(2w)
Turning Down the Refinery Heat
(3w)
A Telomerase Inhibitor Revealed
(3w)
Behold the SpudCell
(3w)
Don't Minimize the Side Effects
(4w)
Speaking Up: Who Is, and Who Isn't
(1mo)
Antibody-Drug Conjugates: Not Quite Worked Out Yet
(1mo)
Here's a Ligand, Go Design a Protein
(1mo)
Machine-Learning Mass Spec Data: Hmmm
(1mo)
Covid-19 Vaccinations and the Heart
(1mo)
Hydroxyl Radicals In Water Droplets? Doesn't Look Like It.
(1mo)
Pharmaphorum
Ipsen' Bylvay fluffs its lines in biliary atresia trial
(2d)
Sanofi gives up on amlitelimab in atopic dermatitis
(2d)
Re-rostered FDA committee backs peptide compounding
(2d)
J&J's multiple myeloma duo aces phase 3 trial
(2d)
Dexcom is first to join FDA/CMS health tech pilot
(3d)
Lilly plans Q1 2027 filing for obesity triple retatrutide
(3d)
EU clears AZ's SERD camizestrant, as FDA review drags on
(3d)
Nuvalent buy delivers new cancer approval for GSK
(3d)
As patents expire, fampridine is cleared for NHS use in MS
(3d)
Takeda gets first OK for orexin narcolepsy drug, in China
(3d)
Repligen builds in cell therapy with $1.5bn BioLife takeover
(4d)
Kaken details the data behind its PI3K inhibitor filing
(4d)
Precision Neuro breaks new ground in BCI technology
(4d)
Gilead, MSD share data on once-weekly oral HIV treatment
(4d)
Trump sets course for 100%, then 200%, tariffs on generics
(4d)
Novo sues Lilly over 'misleading' GLP-1 ad campaigning
(5d)
Agios shares slide as it abandons sickle cell candidate
(5d)
Jasper and Kira merge to build immune-focused biotech
(5d)
Novartis weathers Entresto slump with return to growth
(5d)
New UK PM shuts down science and tech department
(5d)
Drug Discovery Weekly
Wegovy pill could help patients lose 17% body weight
(1mo)
How AskBio is pioneering ‘transformative genetic therapies’ in Parkinson’s disease
(1mo)
Webinar: Learn how to accelerate the early stages of drug discovery
(1mo)
Therapy enables 89% survival rate in myeloma patients
(1mo)
Ulcerative colitis treatment shows best-in-class potential
(1mo)
UK patients to benefit from approval of weight loss tablet
(1mo)
Vertex presents new data on Casgevy in children
(1mo)
DDW Highlights: 16 June 2026
(1mo)
LXR inverse agonist shows promise in liver disease
(1mo)
Guide: One solution – from R&D, to QC
(1mo)
A potentially practice-changing advance in bile duct cancer
(1mo)
Webinar: Consolidate multiple assays into a single, comprehensive AVA test
(1mo)
JAK inhibitor for VEXAS syndrome gets orphan drug designations
(1mo)
Whitepaper: How workflow scheduling software can answer the demands of automated labs
(1mo)
PhoreMost advances brain cancer programme to trial
(1mo)
Oriva appoints Arbat as CEO, advances endometriosis asset
(1mo)
Decoding Pan-RAS(ON) inhibitor activity across KRAS models: Webinar
(1mo)
This week in Drug Discovery (8 June – 12 June)
(1mo)
Laverock reports positive data from oncology programmes
(1mo)
GSK acquires Nuvalent and cancer therapy pipeline
(1mo)
HIT Consultant
Medidata Launches Medidata Plus AI Layer to Standardize Clinical Trial Data and Workflows
(2d)
Wellumio Closes $9.75M to Commercialize Axana Portable Brain Imaging Device
(2d)
Cigna Healthcare Expands AI-Enabled Care Management to Reach 20% More Customers
(2d)
AdvancedMD Expands Waystar-Powered Revenue Cycle Offerings for Independent Practices
(2d)
Candid Health Secures $120M to Expand Autonomous Revenue Cycle Management Platform
(3d)
Karoo Health Secures $16.2M to Build Cardiovascular OS Infrastructure
(3d)
Prosper Medical Secures $16M for AI-Powered Primary Care Platform
(3d)
Teladoc Health Unveils Teladoc One to Deliver Connected, Adaptive Virtual Care
(3d)
Relatient Launches Clinical Request Automation Capability for Dash Voice AI Platform
(3d)
Assured Raises $19M to Replace Manual Credentialing with Autonomous AI Agents
(4d)
Cheiron Raises $8M to Launch AI-Native the Operating System for Drug Programs
(4d)
NVIDIA Launches Open-Source Medical Physics Simulation Framework Within Isaac for Healthcare
(4d)
Flatiron Health Expands Global Oncology Network via First Partnership in Scotland with NHSGGC
(4d)
Bluesight Partners with Pfizer to Integrate SmartDose™ Source-Tagged Medications into KitCheck
(4d)
M&A: Focus to Acquire Managed Services Provider GuideIT
(4d)
KLAS Research Releases 2026 RCM Suites Report: Waystar Leads Market in Overall Satisfaction
(4d)
Healthcare Growth Partners Releases July 2026 Health IT Market Review: Key Valuations and M&A Benchmarks
(4d)
Capability vs. Aspiration: The New Litmus Test for AI in Healthcare
(4d)
M&A: SpinSci Acquires Dialog Health to Expand AI-Powered Patient Access Platform Across Voice and Text
(5d)
The Golden Record: How Health Plan Leaders Can Navigate the Future of Agentic, Actionable Navigation
(5d)
Insights: Pink Sheet
Peptide Industry Reaps Six Wins From RFK Jr.-Remade FDA Panel
(2d)
New ADVOCATE Analysis Backs Tavneos Efficacy, Amgen Tells US FDA In Withdrawal Dispute
(2d)
J&J’s Icotyde Nears EU Finish Line As First Oral IL-23 Receptor Drug For Plaque Psoriasis
(2d)
Second Time Lucky: Minoryx Wins EMA Backing For Nezglyal In cALD
(2d)
EMA Opens EU Door For New Cholesterol-Lowering Drugs From NewAmsterdam And LIB
(2d)
Five Days In December: Vanda Finally Gets Its Hetlioz Hearing
(2d)
GSK Gets EU Thumbs Up For Liver Drug Lynavoy After Success In US & UK
(2d)
Proveca To Challenge EMA Refusal For Ketamine Nasal Spray, Two Other Drugs Also Rejected
(2d)
New US FDA AdComm Members Provide Support For Peptides For Compounding
(2d)
US FDA Advisory Committee Will Revisit Rejection Of Sydnexis’ Pediatric Myopia Drug
(2d)
CDC Nominee Schwartz Gains Key Support After Website Tweak, But Vote Delayed
(3d)
England’s NICE To Update Quality-Of-Life Value Tool For The First Time In 30 Years
(3d)
‘Rather Don’t Submit’: When EMA May Push Back On Filing Dates
(3d)
Spain Looks To Conditional Reimbursement And Dynamic Pricing
(3d)
China Grants Global-First Approval To Takeda’s Narcolepsy Drug
(3d)
HHS Vaccine Panel Charter Rewritten To Include Non-Immunization Strategies
(3d)
Trump’s Generic Tariff Clock Demands Compression Of US FDA Review Timelines
(3d)
If It Sticks, MFN Price Deal For Semaglutide Could Save Medicare A Lot More Than Negotiated Price
(4d)
US-Approved Arimoclomol And Trilaciclib Face High-Stakes EMA Hearings
(4d)
First National HTA Drawing On EU JCA Ends With Ireland Rejecting Novartis’ Itvisma
(4d)
BioXconomy
SEC's semiannual reporting proposal debate continues
(2d)
Emerging IP trends for large molecules, CAR-T therapies, and biosimilars
(2d)
Royalty Pharma takes $425m interest in AZ’s cardiovascular drug
(2d)
Crystalys secures $130m to push gout treatment toward market
(3d)
Samsung Biologics makes bold peptide play with $1.8bn PolyPeptide buy
(3d)
Remote monitoring cuts CRA-CRC interaction
(3d)
Psychedelic renaissance continues as Jupiter Neurosciences licenses MDMA asset
(4d)
Earth's mightiest manufacturers: FDA pilot to supercharge US drug production
(4d)
Implementation science can help translate trial results into healthcare
(4d)
Jeremy Levin's message to Europe: This is your moment – if you choose to act
(4d)
Eyes on Asia: Insilico, Hansoh Pharma, Bora Pharmaceuticals
(5d)
Mission possible: Dimerix gains kidney drug asset for $292m
(5d)
Latigo outlines IPO plans to propel non-opioid pain candidate to market
(6d)
Kalshi lets users bet on drug trial outcomes
(6d)
China's clinical trial advantage: Why biotechs are making the 'go East' decision on day one
(6d)
Finance function faces talent crunch, AI shift
(1w)
Sarepta launches additional Phase III trial to win over EMA for DMD gene therapy
(1w)
Braveheart Bio charts path to independence through Nasdaq debut
(1w)
Chai bags $400m for AI-powered drug discovery
(1w)
Advancing RNA Analysis with Novel Enzymatic Technologies
(1w)
BioCentury
Song among trio of new partners at Venrock
(2d)
Hub 101: Taiwan biotech looks to level up
(2d)
EMA’s CHMP backs two orphan drugs, rebuffs FDA-approved NPC therapy
(2d)
Scribe extends run of strong biotech IPO debuts: Public Equity Report
(2d)
Mapping AI giants’ bets across the biopharma tech stack
(3d)
Science Spotlight: Host-directed antivirals and a bivalent molecular glue
(3d)
Crossovers join Crystalys’ $130M series B: Venture Report
(3d)
Dosing, liver profile may differentiate Arrowhead in severe hypertriglyceridemia
(3d)
Initiate’s Owens on early funding and what it takes to be AI-native
(4d)
Former Black Diamond CEO David Epstein passes away
(4d)
WuXi AppTec’s injunction may hinge on ‘irreparable harm’
(4d)
The next 50 years won’t be defined by borders
(4d)
2026 catalysts: First-half scorecard
(4d)
Series A rounds grew larger as deal count fell in 1H26
(5d)
IPO queue swells as Scribe aims to price this week
(5d)
U.K. cabinet shuffle, Taiwan biotech and Biogen data — a BioCentury podcast
(5d)
With syndicate investing $132M, Jasper merging with Kira: Deals Report
(6d)
WuXi AppTec says 1260H listing based on ‘demonstrably false’ assertions
(6d)
Science Minister Vallance out — U.K. biotech’s latest body blow
(6d)
Axiom’s newborn survival signal, GSK’s chronic cough setback, and more
(6d)
SCRIP
Novo Nordisk Doubles Down On Efforts To Halt Lilly Tirzepatide Ads
(2d)
Merck Signs License Agreements For Monthly PrEP Drug Alimatravir In Developing Countries
(2d)
SMID Caps In The Buyer’s Seat
(2d)
Lundbeck Has Busy Spell Ahead For Readouts And Still Shopping For Gems
(2d)
Pipeline Watch: GSK Drops Camlipixant On Mixed CALM Data
(2d)
Sanofi Shelves Amlitelimab In Atopic Dermatitis After Pipeline Review
(2d)
Ipsen’s Bylvay Miss Shrinks Already-Sparse Biliary Atresia Pipeline
(2d)
As Cipla Chases US Milestone, gVentolin Scale-up Is Key
(2d)
With Jideytro Approval In NSCLC, GSK Has Another ‘Brick’ In Its Oncology Wall
(3d)
Lilly’s Retatrutide Continues To Show Strong Efficacy, But High Side Effects
(3d)
Argenx Momentum On Pace Ahead Of Q3 Data Readouts
(3d)
EU Okays AstraZeneca’s Etcamah As US Wait Continues
(3d)
Executives On The Move: Three CEOs And Three CMOs Among This Week’s Changes
(3d)
Roche Raises Doubts About Future European Pricing Deal For Giredestrant
(3d)
Arcus Adds Summit, AVEO Combinations To ARC-20 Casdatifan Kidney Cancer Study
(3d)
Tecvayli/Talvey Results Showcase Dual-Target Immunotherapy Strategy In Myeloma
(3d)
Takeda Sees Qdenga India Launch By Mid-2027, Panacea Closest Competitor
(3d)
Ribo Upbeat On First-In-Class siRNA In Coronary Artery Disease
(3d)
Dr Reddy’s Semaglutide Woes Ripple Through Partners, CEO Vows Comeback
(3d)
Trump Tariff Action On Generics Highlights Temporary Nature Of Exemptions
(4d)